Core Viewpoint - The company has approved a capital increase of 53 million RMB to the Hefei Hongfeng Equity Investment Fund Center (Limited Partnership) to support the fund's business development [2][6]. Group 1: Board Meeting and Decision - The company's 10th fourth (temporary) board meeting was held on December 29, 2025, with all six attending directors present, and the meeting was chaired by Chairman Li Yang [1]. - The board unanimously approved the proposal to increase capital to the Hefei Hongfeng Equity Investment Fund Center [2][3]. Group 2: Investment Fund Overview - The company initially invested 150 million RMB to establish the Hefei Hongfeng Equity Investment Fund Center [5]. - The fund completed its private investment fund registration on February 5, 2024, with the China Securities Investment Fund Industry Association [5]. Group 3: Capital Increase Details - The total capital increase for the fund amounts to 120 million RMB, with the company's contribution being 53 million RMB [6]. - The fund's scale will increase from 310 million RMB to 430 million RMB following this capital increase [6]. Group 4: Impact and Compliance - The capital increase will not affect the company's normal operations or financial status significantly [6]. - The investment does not constitute a related party transaction or a major asset restructuring as per regulations [6].
安徽丰原药业股份有限公司 第十届四次(临时)董事会决议公告